SAN DIEGO, June 14, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Charles J. Fisher, Jr. M.D., Chief Executive Officer, and James Frakes, Chief Financial Officer, will present a company overview at the Healthcare Virtual Conference, presented by Maxim Group and hosted by M-Vest, on Wednesday, June 21, 2023, at 4:00 PM ET.
The conference will be presented live on M-Vest. To attend, sign up to become an M-Vest member by clicking here.
Management of Aethlon Medical will also be participating in virtual one-on-one meetings with investors during the conference, being held June 20-22, 2023. To schedule a meeting with management outside of the conference, contact Susan Noonan at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Additional information can be found at www.AethlonMedical.com.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.14 |
| Daily Change: | -0.03 -2.56 |
| Daily Volume: | 49,926 |
| Market Cap: | US$2.290M |
August 13, 2025 June 26, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
